Vaxcyte Inc. Common Stock vs Vistra Corp — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while Vistra Corp trades at $149.15 (market cap $54.49B). The key difference: Vistra Corp is far larger — about 5.2× Vaxcyte Inc. Common Stock's market cap, and Vistra Corp pays a 0.57% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Vistra Corp for 33 Days on average.
| PCVX | VST | |
|---|---|---|
Market Cap | $10.51B | $54.49B |
Volume | 2,644,694 | 5,289,982 |
Sector | Health | Utilities |
52-Week High | $73.82 | $210.85 |
52-Week Low | $40.32 | $134.71 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $9.14B | $76.43B |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Vistra Corp (VST) trades at $162.36, up 2.68% with strong institutional support and bullish technical indicators. The stock shows impressive profitability with 75.73% ROE and 11.55% net margin, though recent earnings were mixed with Q1 beat but Q2 miss. Recent developments include a $4.2 billion government loan for nuclear expansion and a 20-year power deal with New Era Energy, positioning VST to capitalize on AI-driven electricity demand.
Vistra presents significant upside potential with a $215.23 consensus price target (32.5% upside) and 91.3% buy ratings. The company benefits from nuclear power expansion and AI infrastructure demand, though risks include execution of growth initiatives and energy market volatility. Current valuation at 27.38 P/E appears reasonable given growth prospects in the power generation sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →